Jon Glass, MD

Contact Dr. Glass

909 Walnut Street
Philadelphia, PA 19107

(215) 503-7005
(215) 503-9357 fax

Most Recent Peer-reviewed Publications

  1. Reply to M.C. Chamberlain
  2. Phase I and II study of induction chemotherapy with methotrexate, rituximab, and temozolomide, followed by whole-brain radiotherapy and postirradiation temozolomide for primary CNS lymphoma: NRG oncology RTOG 0227
  3. Primary central nervous system Epstein–Barr virus-positive diffuse large B-cell lymphoma of the elderly: a clinicopathologic study of five cases
  4. Targeting metabolism with a ketogenic diet during the treatment of glioblastoma multiforme
  5. A pilot study of hypofractionated stereotactic radiation therapy and sunitinib in previously irradiated patients with recurrent high-grade glioma
  6. A 60-year-old indian male with altered sensorium and extensive lymphoma of the scalp
  7. A phase i study of the combination of sorafenib with temozolomide and radiation therapy for the treatment of primary and recurrent high-grade gliomas
  8. Improving prognosis of glioblastoma in the 21st century: Who has benefited most?
  9. Characterization and outcomes of optic nerve gliomas: A population-based analysis
  10. Intravascular lymphoma of the CNS
  11. A phase 1b trial of the combination of the antiangiogenic agent sunitinib and radiation therapy for patients with primary and metastatic central nervous system malignancies
  12. Hypofractionated stereotactic radiation therapy: An effective therapy for recurrent high-grade gliomas
  13. Replacing a dopamine agonist by the COMT-inhibitor tolcapone as an adjunct to l-dopa in the treatment of Parkinson's disease: A randomized, multicenter, open-label, parallel-group study
  14. Central nervous system cancers: Clinical Practice Guidelines in Oncology™
  15. Radiation-induced tumor after stereotactic radiosurgery for an arteriovenous malformation: Case report
  16. Unexpected dementia following prophylactic cranial irradiation for small cell lung cancer: Case report
  17. Temozolomide treatment of refractory epilepsy in a patient with an oligodendroglioma
  18. Neurologic Complications of Lymphoma and Leukemia
  19. The Parkinson-control study: A 1-year randomize, double-blind trial comapring piribedil (150 mg/day) with bromocriptine (25 mg/day) in early combination with levodopa in Parkinson's disease
  20. Central nervous system cancers Clinical Practice Guidelines in Oncology